These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

129 related articles for article (PubMed ID: 34387606)

  • 1. Case report: ado-trastuzumab as second-line treatment in HER2 positive salivary duct carcinoma.
    Taha T; Billan S
    Anticancer Drugs; 2022 Jan; 33(1):e760-e763. PubMed ID: 34387606
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Case series of docetaxel, trastuzumab, and pertuzumab (DTP) as first line anti-HER2 therapy and ado-trastuzumab emtansine (T-DM1) as second line for recurrent or metastatic HER2-positive salivary duct carcinoma.
    Uijen MJM; Lassche G; van Engen-van Grunsven ACH; Driessen CML; van Herpen CML
    Oral Oncol; 2022 Feb; 125():105703. PubMed ID: 34995931
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Exceptional responses to pertuzumab, trastuzumab, and docetaxel in human epidermal growth factor receptor-2 high expressing salivary duct carcinomas.
    Park JC; Ma TM; Rooper L; Hembrough T; Foss RD; Schmitt NC; Sawhney R; Flanders A; Kang H
    Head Neck; 2018 Dec; 40(12):E100-E106. PubMed ID: 30478962
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Systemic therapy in the management of recurrent or metastatic salivary duct carcinoma: A systematic review.
    Uijen MJM; Lassche G; van Engen-van Grunsven ACH; Tada Y; Verhaegh GW; Schalken JA; Driessen CML; van Herpen CML
    Cancer Treat Rev; 2020 Sep; 89():102069. PubMed ID: 32717621
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Role of ado-trastuzumab emtansine (T-DM1) in HER2 positive salivary gland tumour with brain metastasis.
    Dhamne N; Koyyala VPB; Chougule S; Pawar S
    BMJ Case Rep; 2022 May; 15(5):. PubMed ID: 35641086
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The Clinical Utilisation and Duration of Treatment with HER2-Directed Therapies in HER2-Positive Recurrent or Metastatic Salivary Gland Cancers.
    Haigh JE; Patel K; Rack S; Jiménez-Labaig P; Betts G; Harrington KJ; Metcalf R
    Curr Oncol; 2024 Sep; 31(9):5652-5661. PubMed ID: 39330047
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Human epidermal receptor 2-amplified salivary duct carcinoma: regression with dual human epidermal receptor 2 inhibition and anti-vascular endothelial growth factor combination treatment.
    Falchook GS; Lippman SM; Bastida CC; Kurzrock R
    Head Neck; 2014 Mar; 36(3):E25-7. PubMed ID: 23852769
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Ado-trastuzumab emtansine: a HER2-positive targeted antibody-drug conjugate.
    Corrigan PA; Cicci TA; Auten JJ; Lowe DK
    Ann Pharmacother; 2014 Nov; 48(11):1484-93. PubMed ID: 25082874
    [TBL] [Abstract][Full Text] [Related]  

  • 9. T-DM1 Efficacy in Patients With HER2-positive Metastatic Breast Cancer Progressing After a Taxane Plus Pertuzumab and Trastuzumab: An Italian Multicenter Observational Study.
    Conte B; Fabi A; Poggio F; Blondeaux E; Dellepiane C; D'Alonzo A; Buono G; Arpino G; Magri V; Naso G; Presti D; Mura S; Fontana A; Cognetti F; Molinelli C; Pastorino S; Bighin C; Miglietta L; Boccardo F; Lambertini M; Del Mastro L;
    Clin Breast Cancer; 2020 Apr; 20(2):e181-e187. PubMed ID: 31735691
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Significant and durable clinical benefit from trastuzumab in 2 patients with HER2-amplified salivary gland cancer and a review of the literature.
    Thorpe LM; Schrock AB; Erlich RL; Miller VA; Knost J; Le-Lindqwister N; Jujjavarapu S; Ali SM; Liu JJ
    Head Neck; 2017 Mar; 39(3):E40-E44. PubMed ID: 28006087
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Targeted therapy with trastuzumab for advanced salivary ductal carcinoma: case report and literature review.
    Kaidar-Person O; Billan S; Kuten A
    Med Oncol; 2012 Jun; 29(2):704-6. PubMed ID: 21380780
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Neoadjuvant trastuzumab, pertuzumab, and chemotherapy versus trastuzumab emtansine plus pertuzumab in patients with HER2-positive breast cancer (KRISTINE): a randomised, open-label, multicentre, phase 3 trial.
    Hurvitz SA; Martin M; Symmans WF; Jung KH; Huang CS; Thompson AM; Harbeck N; Valero V; Stroyakovskiy D; Wildiers H; Campone M; Boileau JF; Beckmann MW; Afenjar K; Fresco R; Helms HJ; Xu J; Lin YG; Sparano J; Slamon D
    Lancet Oncol; 2018 Jan; 19(1):115-126. PubMed ID: 29175149
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Combination of docetaxel, trastuzumab and pertuzumab or treatment with trastuzumab-emtansine for metastatic salivary duct carcinoma.
    van Boxtel W; Boon E; Weijs WLJ; van den Hoogen FJA; Flucke UE; van Herpen CML
    Oral Oncol; 2017 Sep; 72():198-200. PubMed ID: 28673692
    [No Abstract]   [Full Text] [Related]  

  • 14. Second-Line Treatment of HER2-Positive Salivary Gland Tumor: Ado-Trastuzumab Emtansine (T-DM1) after Progression on Trastuzumab.
    Corrêa TS; Matos GDR; Segura M; Dos Anjos CH
    Case Rep Oncol; 2018; 11(2):252-257. PubMed ID: 29867432
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [A case of metastatic salivary duct carcinoma successfully treated with trastuzumab-based targeted therapy].
    Iguchi F; Taniguchi Z; Kusano J; Takahashi Y; Murai N
    Nihon Jibiinkoka Gakkai Kaiho; 2014 Aug; 117(8):1108-14. PubMed ID: 25255650
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Trastuzumab for the treatment of salivary duct carcinoma.
    Limaye SA; Posner MR; Krane JF; Fonfria M; Lorch JH; Dillon DA; Shreenivas AV; Tishler RB; Haddad RI
    Oncologist; 2013; 18(3):294-300. PubMed ID: 23429737
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Trastuzumab Emtansine for Residual Invasive HER2-Positive Breast Cancer.
    von Minckwitz G; Huang CS; Mano MS; Loibl S; Mamounas EP; Untch M; Wolmark N; Rastogi P; Schneeweiss A; Redondo A; Fischer HH; Jacot W; Conlin AK; Arce-Salinas C; Wapnir IL; Jackisch C; DiGiovanna MP; Fasching PA; Crown JP; Wülfing P; Shao Z; Rota Caremoli E; Wu H; Lam LH; Tesarowski D; Smitt M; Douthwaite H; Singel SM; Geyer CE;
    N Engl J Med; 2019 Feb; 380(7):617-628. PubMed ID: 30516102
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Metastatic HER-2-positive salivary gland carcinoma treated with trastuzumab and a taxane: a series of six patients.
    De Block K; Vander Poorten V; Dormaar T; Nuyts S; Hauben E; Floris G; Deroose CM; Schöffski P; Clement PM
    Acta Clin Belg; 2016 Dec; 71(6):383-388. PubMed ID: 27285571
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A multicenter Phase II study evaluating the efficacy, safety and pharmacokinetics of trastuzumab emtansine in Japanese patients with heavily pretreated HER2-positive locally recurrent or metastatic breast cancer.
    Kashiwaba M; Ito Y; Takao S; Doihara H; Rai Y; Kanatani K; Takashima S; Masuda N
    Jpn J Clin Oncol; 2016 May; 46(5):407-14. PubMed ID: 26917603
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Treatment patterns and outcomes of palliative systemic therapy in patients with salivary duct carcinoma and adenocarcinoma, not otherwise specified.
    Sousa LG; Wang K; Torman D; Binks BJ; Rubin ML; Andersen CR; Lewis WE; Rivera MJ; Kaya D; El-Naggar AK; Hanna EY; Esmaeli B; Frank SJ; Bell D; Glisson BS; Rodon J; Meric-Bernstam F; Lee JJ; Ferrarotto R
    Cancer; 2022 Feb; 128(3):509-518. PubMed ID: 34661906
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.